Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC2R | Q01718 | 15/20 | 0.86 |
| ▸ | HTR1B | P28222 | 1/20 | 0.86 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atumelnant SCHEMBL29932180 | 0.92 | MC2R (1.00) | MC2RHTR1B | |
| Atumelnant SCHEMBL22382763 | 0.92 | MC2R (1.00) | MC2RHTR1B | |
| Atumelnant SCHEMBL21700563 | 0.92 | MC2R (1.00) | MC2RHTR1B | |
| Atumelnant SCHEMBL29931824 | 0.92 | MC2R (1.00) | MC2RHTR1B | |
| Atumelnant SCHEMBL30897579 | 0.89 | MC2R (0.93) | MC2RHTR1B | |
| Atumelnant SCHEMBL30897580 | 0.89 | MC2R (0.93) | MC2RHTR1B | |
| SCHEMBL21700995 | 0.88 | MC2R (1.00) | MC2RHTR1B | |
| SCHEMBL31188578 | 0.88 | MC2R (0.90) | MC2RHTR1B | |
| SCHEMBL21700775 | 0.88 | MC2R (0.90) | MC2RHTR1B | |
| Atumelnant SCHEMBL30897581 | 0.87 | MC2R (0.89) | MC2RHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885CTSS 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.